Sionna Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SION research report →
Range $5 – $60
Price Chart
About the company
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
- CEO
- Michael Cloonan
- IPO
- 2025
- Employees
- 59
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on SION
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $258.49M
- P/E
- -2.63
- PEG
- 0.11
- P/S
- 0.00
- P/B
- 0.97
- EV/EBITDA
- -2.18
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.94%
- ROIC
- -39.98%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-647,000+3.1%
- Op Income
- $-88,982,000
- Net Income
- $-75,268,000-22.0%
- EPS
- $-1.88-34.3%
- OCF Growth
- -25.6%
- FCF Growth
- -26.2%
- 52W High
- $54.97
- 52W Low
- $4.01
- 50D MA
- $37.24
- 200D MA
- $38.94
- Beta
- 1.32
- RSI (14)
- 22
- Avg Volume
- 1.70M
No earnings-call transcripts are available for SION yet.
- Free Float
- 58.9%
- Shares Outstanding
- 45.15M
- Float Shares
- 26.61M
of shares held by institutions
101 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.18M | ▲ 41.80K |
| Cibc Private Wealth Group, LLC | 4.50K | ▲ 4.50K |
| California State Teachers Retirement System | 868 | ▼ 120 |
| Cwm, LLC | 67 | ▼ 13 |
Held by 162 ETFs
Biggest fund positions in SION by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 7, 26 | Thompson Peter A. | sell | 85,918 |
| Jul 7, 26 | ORBIMED ADVISORS LLC | sell | 85,918 |
| Jul 6, 26 | Fitzpatrick Jennifer | other | 10,250 |
| Jul 6, 26 | Fitzpatrick Jennifer | other | 10,250 |
| Jul 6, 26 | Fitzpatrick Jennifer | sell | 10,250 |
| Jun 30, 26 | Thompson Peter A. | sell | 115,844 |
| Jun 30, 26 | ORBIMED ADVISORS LLC | sell | 115,844 |
| Jun 17, 26 | Stelzer Laurie | other | 17,340 |
| Jun 17, 26 | Viney Joanne L. | other | 17,340 |
| Jun 17, 26 | Thompson Peter A. | other | 17,340 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SION coverage
Recent articles, reports, and earnings notes.
No research on SION yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SION report →Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
gurufocus.com · Aug 19
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics
prnewswire.com · Aug 19
Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky
gurufocus.com · Aug 19
Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky
prnewswire.com · Aug 19
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
gurufocus.com · Aug 19
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
businesswire.com · Aug 19
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced -- Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
gurufocus.com · Aug 18
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
businesswire.com · Aug 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.